Literature DB >> 8948029

Mutations and expression of the ras family genes in leukemias.

D M Gougopoulou1, H Kiaris, M Ergazaki, N I Anagnostopoulos, V Grigoraki, D A Spandidos.   

Abstract

The levels of expression and the incidence of codon 12 point mutations of the ras family genes were studied in 18 cases of leukemia, seven with acute myeloblastic leukemia (AML), three with acute lymphoblastic leukemia (ALL), four cases with chronic myelogenic leukemia (CML) and four cases with chronic lymphocytic leukemia (CLL). Elevated expression of the ras genes was found for 39%, 61% and 67% of the specimens for the H-ras, K-ras and N-ras, respectively. A trend was found between the overexpression of the N-ras gene and the acute leukemias: all 10 acute leukemias exhibited overexpression of the N-ras gene, while only two of the CML cases, both in blastic crisis, showed elevated levels of the N-ras gene. Codon 12 point mutations at the N-ras gene were found in two of seven cases (28%) with AML and one of four cases (25%) with CML. The only K-ras codon 12 point mutation was found in a patient with CLL. No mutations were found in the codon 12 of H-ras. Our data suggest that apart from the point mutations, overexpression of the ras family genes is important in the development of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8948029     DOI: 10.1002/stem.140725

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  9 in total

Review 1.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

2.  Oncogenic NRAS, KRAS, and HRAS exhibit different leukemogenic potentials in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

Review 4.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

5.  Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice.

Authors:  Chaitali Parikh; Ramesh Subrahmanyam; Ruibao Ren
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

6.  New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing.

Authors:  Elena Doménech; Gonzalo Gómez-López; Daniel Gzlez-Peña; Mar López; Beatriz Herreros; Juliane Menezes; Natalia Gómez-Lozano; Angel Carro; Osvaldo Graña; David G Pisano; Orlando Domínguez; José A García-Marco; Miguel A Piris; Margarita Sánchez-Beato
Journal:  PLoS One       Date:  2012-06-01       Impact factor: 3.240

7.  Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells.

Authors:  Oshrat Hershkovitz Rokah; Galit Granot; Adelina Ovcharenko; Shira Modai; Metsada Pasmanik-Chor; Amos Toren; Noam Shomron; Ofer Shpilberg
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

8.  Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling.

Authors:  Otto Kauko; Teemu Daniel Laajala; Mikael Jumppanen; Petteri Hintsanen; Veronika Suni; Pekka Haapaniemi; Garry Corthals; Tero Aittokallio; Jukka Westermarck; Susumu Y Imanishi
Journal:  Sci Rep       Date:  2015-08-17       Impact factor: 4.379

9.  A comprehensive survey of Ras mutations in cancer.

Authors:  Ian A Prior; Paul D Lewis; Carla Mattos
Journal:  Cancer Res       Date:  2012-05-15       Impact factor: 12.701

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.